NEW YORK, Aug. 8 – Lexicon Genetics said on Wednesday that Bristol-Myers Squibb has chosen certain drug targets from Lexicon’s LexVision library of mouse gene knockout data to move into drug development.

The drug giant's decision is significant, Lexicon Chief Financial Officer Julia Gregory told GenomeWeb , because it is the first time a subscriber to the database has identified particularly promising drug targets.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Five researchers are to share this year's Albany Medical Center Prize for their work on the CRISPR/Cas9 gene-editing tool, the AP reports.

Stat News reports on how white supremacists cope with surprising genetic ancestry testing results.

In Genome Research this week: sex-biased gene expression evolution in malaria mosquitos, method to find ancient selective sweeps, and more.

Iceland has nearly eliminated Down syndrome from its population, CBS News reports.